Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data

Both pembrolizumab (P) and combination of pembrolizumab with platinum-based chemotherapy (PCT) represent standard 1(st)-line options for advanced non-small cell lung cancer (aNSCLC) with PD-L1 tumor proportion score (TPS) ≥50%. The two strategies have never been compared in a randomized trial. 256 c...

Descripción completa

Detalles Bibliográficos
Autores principales: Dudnik, Elizabeth, Moskovitz, Mor, Rottenberg, Yakir, Lobachov, Anastasiya, Mandelboim, Rinat, Shochat, Tzippy, Urban, Damien, Wollner, Mira, Nechushtan, Hovav, Rotem, Ofer, Zer, Alona, Daher, Sameh, Bar, Jair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849771/
https://www.ncbi.nlm.nih.gov/pubmed/33552685
http://dx.doi.org/10.1080/2162402X.2020.1865653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849771/
https://www.ncbi.nlm.nih.gov/pubmed/33552685
http://dx.doi.org/10.1080/2162402X.2020.1865653

Ejemplares similares